NYSE:COO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

The Cooper Companies, Inc. operates as a medical device company worldwide. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Cooper Companies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: COO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: COO's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-5.2%

COO

-4.2%

US Medical Equipment

-2.4%

US Market


1 Year Return

14.2%

COO

28.5%

US Medical Equipment

31.2%

US Market

Return vs Industry: COO underperformed the US Medical Equipment industry which returned 28.5% over the past year.

Return vs Market: COO underperformed the US Market which returned 31.2% over the past year.


Shareholder returns

COOIndustryMarket
7 Day-5.2%-4.2%-2.4%
30 Day-0.9%-5.3%-3.0%
90 Day7.5%0.9%3.2%
1 Year14.3%14.2%29.6%28.5%34.1%31.2%
3 Year49.6%49.5%63.3%59.3%48.1%38.6%
5 Year149.6%149.3%144.0%126.5%116.5%92.3%

Long-Term Price Volatility Vs. Market

How volatile is Cooper Companies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cooper Companies undervalued compared to its fair value and its price relative to the market?

76.53x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: COO ($371.56) is trading above our estimate of fair value ($285.65)

Significantly Below Fair Value: COO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: COO is poor value based on its PE Ratio (76.5x) compared to the US Medical Equipment industry average (50.6x).

PE vs Market: COO is poor value based on its PE Ratio (76.5x) compared to the US market (21x).


Price to Earnings Growth Ratio

PEG Ratio: COO is poor value based on its PEG Ratio (4.2x)


Price to Book Ratio

PB vs Industry: COO is good value based on its PB Ratio (4.8x) compared to the US Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Cooper Companies forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

18.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COO's forecast earnings growth (18.2% per year) is above the savings rate (2%).

Earnings vs Market: COO's earnings (18.2% per year) are forecast to grow slower than the US market (19.5% per year).

High Growth Earnings: COO's earnings are forecast to grow, but not significantly.

Revenue vs Market: COO's revenue (7.2% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: COO's revenue (7.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COO's Return on Equity is forecast to be low in 3 years time (14%).


Next Steps

Past Performance

How has Cooper Companies performed over the past 5 years?

9.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COO has a large one-off loss of $90.1M impacting its October 31 2020 financial results.

Growing Profit Margin: COO's current net profit margins (9.8%) are lower than last year (17.6%).


Past Earnings Growth Analysis

Earnings Trend: COO's earnings have grown by 9.8% per year over the past 5 years.

Accelerating Growth: COO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: COO had negative earnings growth (-48.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (9.8%).


Return on Equity

High ROE: COO's Return on Equity (6.2%) is considered low.


Next Steps

Financial Health

How is Cooper Companies's financial position?


Financial Position Analysis

Short Term Liabilities: COO's short term assets ($1.3B) exceed its short term liabilities ($1.0B).

Long Term Liabilities: COO's short term assets ($1.3B) do not cover its long term liabilities ($1.9B).


Debt to Equity History and Analysis

Debt Level: COO's debt to equity ratio (47.3%) is considered high.

Reducing Debt: COO's debt to equity ratio has reduced from 50.5% to 47.3% over the past 5 years.

Debt Coverage: COO's debt is well covered by operating cash flow (26.9%).

Interest Coverage: COO's interest payments on its debt are well covered by EBIT (10.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Cooper Companies's current dividend yield, its reliability and sustainability?

0.016%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: COO's dividend (0.016%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.34%).

High Dividend: COO's dividend (0.016%) is low compared to the top 25% of dividend payers in the US market (3.72%).


Stability and Growth of Payments

Stable Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: COO is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Al White (50 yo)

2.83yrs

Tenure

US$9,584,027

Compensation

Mr. Albert G. White, III, also known as Al, has been President, Chief Executive Officer and Non-Independent Director of The Cooper Companies, Inc. since May 1, 2018. Mr. White served as Chief Financial Off...


CEO Compensation Analysis

Compensation vs Market: Al's total compensation ($USD9.58M) is about average for companies of similar size in the US market ($USD10.58M).

Compensation vs Earnings: Al's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Albert White
President2.83yrsUS$9.58m0.084%
$ 15.4m
Brian Andrews
Executive VP2.83yrsUS$2.30m0.0065%
$ 1.2m
Daniel McBride
Executive VP & COO7.33yrsUS$3.38m0.070%
$ 12.7m
Holly Sheffield
President of CooperSurgical0.67yrUS$2.55m0.0063%
$ 1.1m
Agostino Ricupati
Senior VP of Finance & Tax and Chief Accounting Officer3.42yrsUS$1.21m0.0049%
$ 887.4k
Kim Duncan
Vice President of Investor Relations & Risk Management6.33yrsno datano data
Mark Drury
VP, General Counsel & Corporate Secretary1.08yrsno data0.0030%
$ 547.8k
Juan Aragón
President of CooperVision Specialty EyeCare Division3.08yrsno datano data

3.0yrs

Average Tenure

49.5yo

Average Age

Experienced Management: COO's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Albert White
President2.83yrsUS$9.58m0.084%
$ 15.4m
Allan Rubenstein
Independent Vice Chairman & Lead Director18.67yrsUS$603.51k0.0065%
$ 1.2m
A. Bender
Independent Chairman18.67yrsUS$739.22k0.038%
$ 6.9m
Robert Weiss
Non-Independent Director25.17yrsUS$562.34k0.29%
$ 52.8m
Teresa Madden
Independent Director0.25yrno data0.00018%
$ 32.9k
William Kozy
Independent Director4.92yrsUS$587.84k0.0080%
$ 1.5m
Gary Petersmeyer
Independent Director8.17yrsUS$579.34k0.0027%
$ 496.7k
Jody Lindell
Independent Director15.17yrsUS$594.84k0.038%
$ 7.0m
Colleen Jay
Independent Director4.92yrsUS$583.34k0.0074%
$ 1.4m

8.2yrs

Average Tenure

69yo

Average Age

Experienced Board: COO's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

The Cooper Companies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: The Cooper Companies, Inc.
  • Ticker: COO
  • Exchange: NYSE
  • Founded: 1980
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$18.260b
  • Shares outstanding: 49.14m
  • Website: https://www.coopercos.com

Number of Employees


Location

  • The Cooper Companies, Inc.
  • 6101 Bollinger Canyon Road
  • Suite 500
  • San Ramon
  • California
  • 94583
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
COONYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1983
CP6DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1983
COO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1983
0I3ILSE (London Stock Exchange)YesCommon StockGBUSDJan 1983
C1OO34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 10 REPR 1 COMBRBRLJan 2020

Biography

The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of cont...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/05 00:05
End of Day Share Price2021/03/04 00:00
Earnings2020/10/31
Annual Earnings2020/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.